These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 11956031

  • 1. Circulating macrophage colony stimulating factor as a marker of tumour progression.
    McDermott RS, Deneux L, Mosseri V, Védrenne J, Clough K, Fourquet A, Rodriguez J, Cosset JM, Sastre X, Beuzeboc P, Pouillart P, Scholl SM.
    Eur Cytokine Netw; 2002; 13(1):121-7. PubMed ID: 11956031
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S, Szmitkowski M, Wojtukiewicz M.
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [Abstract] [Full Text] [Related]

  • 4. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
    Ławicki S, Czygier M, Omyła J, Bedkowska E, Szmitkowski M.
    Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
    [Abstract] [Full Text] [Related]

  • 5. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
    Mroczko B, Groblewska M, Wereszczyńska-Siemiatkowska U, Okulczyk B, Kedra B, Łaszewicz W, Dabrowski A, Szmitkowski M.
    Clin Chim Acta; 2007 May 01; 380(1-2):208-12. PubMed ID: 17368603
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
    Smith HO, Anderson PS, Kuo DY, Goldberg GL, DeVictoria CL, Boocock CA, Jones JG, Runowicz CD, Stanley ER, Pollard JW.
    Clin Cancer Res; 1995 Mar 01; 1(3):313-25. PubMed ID: 9815987
    [Abstract] [Full Text] [Related]

  • 8. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Mar 01; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells.
    Silva HC, Garcao F, Coutinho EC, De Oliveira CF, Regateiro FJ.
    Neoplasma; 2006 Mar 01; 53(6):538-43. PubMed ID: 17167725
    [Abstract] [Full Text] [Related]

  • 11. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
    Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J.
    Cancer Radiother; 2004 Jun 01; 8(3):155-67. PubMed ID: 15217583
    [Abstract] [Full Text] [Related]

  • 12. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR.
    J Natl Cancer Inst; 2007 Feb 07; 99(3):196-205. PubMed ID: 17284714
    [Abstract] [Full Text] [Related]

  • 13. Serum big endothelin-1 levels in female patients with breast cancer.
    Yildirim Y, Gunel N, Coskun U, Sancak B, Bukan N, Aslan S, Cetin A.
    Int Immunopharmacol; 2008 Aug 07; 8(8):1119-23. PubMed ID: 18550016
    [Abstract] [Full Text] [Related]

  • 14. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T, Kinjo M, Nutahara K, Higashihara E.
    Int J Urol; 2006 Sep 07; 13(9):1197-201. PubMed ID: 16984552
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.
    Wong NS, Kahn HJ, Zhang L, Oldfield S, Yang LY, Marks A, Trudeau ME.
    Breast Cancer Res Treat; 2006 Sep 07; 99(1):63-9. PubMed ID: 16541316
    [Abstract] [Full Text] [Related]

  • 16. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M.
    Obstet Gynecol; 1993 Dec 07; 82(6):946-50. PubMed ID: 8233270
    [Abstract] [Full Text] [Related]

  • 17. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
    Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, Damala K, Vassou A, Vartholomatos G, Kolaitis N, Pavlidis N.
    Cancer; 2004 Oct 15; 101(8):1767-75. PubMed ID: 15386335
    [Abstract] [Full Text] [Related]

  • 18. Serum levels of hepatocyte growth factor in patients with breast cancer.
    Sheen-Chen SM, Liu YW, Eng HL, Chou FF.
    Cancer Epidemiol Biomarkers Prev; 2005 Mar 15; 14(3):715-7. PubMed ID: 15767355
    [Abstract] [Full Text] [Related]

  • 19. The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer.
    Lowery AJ, Sweeney KJ, Molloy AP, Hennessy E, Curran C, Kerin MJ.
    BMC Cancer; 2008 Sep 30; 8():279. PubMed ID: 18826631
    [Abstract] [Full Text] [Related]

  • 20. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
    ławicki S, Czygier M, Gacuta-Szumarska E, Knapp P, Szmitkowski M.
    Pol Merkur Lekarski; 2006 Nov 30; 21(125):465-8. PubMed ID: 17345841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.